Cargando…
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
AIMS: As sacubitril/valsartan may potentiate early natriuresis, expert consensus documents recommend diuretic dose reduction on first initiation. However, there are limited data on the effects of sacubitril/valsartan on the background of varying diuretic regimens or on diuretic requirements over tim...
Autores principales: | Chatur, Safia, Claggett, Brian L., Vardeny, Orly, Jering, Karola, Desai, Akshay S., Pfeffer, Marc A., Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D., Vaduganathan, Muthiah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092840/ https://www.ncbi.nlm.nih.gov/pubmed/36181769 http://dx.doi.org/10.1002/ejhf.2703 |
Ejemplares similares
-
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022) -
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022) -
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2019) -
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021) -
Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)